Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study

ABSTRACT Background Effective management of scalp psoriasis needs treatment with high patient preference and treatment satisfaction. Clinical trials show promising results for calcipotriene and betamethasone dipropionate cream based on polyaphron dispersion (PAD) technology (CAL/BDP PAD‐cream). However, real‐world data are scarce. Objectives To evaluate patient‐ and clinician‐reported outcomes and impact of adherence on treatment outcomes of CAL/BDP PAD‐cream in adults with mild‐to‐moderate scalp psoriasis in real‐world settings in Europe. Methods PRO‐SCALP is an ongoing observational, multicentre cohort study, collecting data primarily at baseline and Week 8 (end of the study, EOS). Patient self‐assessments included Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM‐9), Scalpdex questionnaire, Worst Itch‐Numerical Rating Scale (WI‐NRS), sleep patterns, personal preferences and adherence to CAL/BDP PAD‐cream using a visual analogue scale (VAS). Clinicians' assessments included physician global assessment of scalp (scalp‐PGA) and S‐mPASI. Results Of 152 patients included in this interim analysis, 134 patients (mean age: 48.4 years; 69.4% females) had evaluable outcome data. At EOS, mean (SD) patient satisfaction scores (TSQM‐9) were—effectiveness: 76.0 (23.9), convenience of use: 70.2 (21.3), global satisfaction: 76.1 (22.5). At Week 8, 79.0% of patients attained a scalp‐PGA score of 0 (clear) or 1 (almost clear), and 71.0% attained scalp‐PGA success, defined as a scalp PGA score of 0/1 and ≥ 2‐points improvement in scalp‐PGA score change from baseline (CFB). CFB of S‐mPASI scores, patient‐reported symptoms, emotions, functioning and overall Scalpdex scores as well as WI‐NRS scores improved significantly ( p < 0.0001) at EOS, within both low‐adherence (VAS < 80) and high‐adherence (VAS: 80−100) groups. Across key outcome measures, CFB of treatment outcomes was found to be better in patients with higher adherence. Conclusions Findings of the study indicate high treatment satisfaction, significant improvement in clinical outcomes and patients' quality of life associated with CAL/BDP PAD‐cream, especially in patients with higher adherence.